New drug cocktail aims to shrink Hard-to-Treat lung tumors

NCT ID NCT07670013

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This phase 2 trial tests a combination of two drugs—lucankizumab and goleirex—as a first treatment for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study will enroll 43 participants to see if the combo shrinks tumors and how safe it is. If it works, it could provide a new option for this hard-to-treat cancer type.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lucankizumab (SKB264) plus goleirex (KRAS G12C inhibitor)
What this could lead to: If successful, this combination could offer a new first-line treatment option that shrinks tumors and delays progression for people with a specific type of advanced lung cancer.
What could go wrong: This is a small, early-phase trial with only 43 participants, so results may not apply to everyone. The combination may cause side effects, and it is not yet known if it improves survival compared to existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

2nd Affiliated Hospital, School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.